&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-11-08, 06:00

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-11-05, 19:00

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Etsuko Liu

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-11-03, 20:00

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-21, 09:16

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-21, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-21, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-21, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-06, 18:00

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
Bud Eliott

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-07-30, 18:00

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Tony Loman

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-04-07, 18:30

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Danny Gaylord

Notified -

Popular Posts